sorafenib has been researched along with Hydrophobia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koraka, P; Kycko, A; Marzec, A; Orłowska, A; Osterhaus, A; Reichert, M; Smreczak, M; Trębas, P; Żmudziński, JF | 1 |
| Baumgärtner, W; Gerhauser, I; Koraka, P; Martina, BEE; Marzec, A; Orlowska, A; Osterhaus, ADME; Roose, JM; Smreczak, M; Trebas, P; Wohlsein, P; Zmudzinski, J | 1 |
2 other study(ies) available for sorafenib and Hydrophobia
| Article | Year |
|---|---|
The effect of selected molecules influencing the detrimental host immune response on a course of rabies virus infection in a murine model.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cricetinae; Disease Models, Animal; Female; Immunity, Innate; Interleukin-6; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Rabies; Rabies virus; Sorafenib; Tumor Necrosis Factor-alpha | 2019 |
Combination drug treatment prolongs survival of experimentally infected mice with silver-haired bat rabies virus.
Topics: Animals; Apoptosis; Brain; Cell Line, Tumor; Chiroptera; Female; Infliximab; Mannitol; Mice; Mice, Inbred C57BL; Post-Exposure Prophylaxis; Pyroptosis; Rabies; RNA, Viral; Sorafenib; Spinal Cord | 2019 |